Introduction {#s001}
============

C[hildren, adolescents]{.smallcaps}, and adults with attention-deficit/hyperactivity disorder (ADHD) frequently present with a variety of sleep-related difficulties before receiving ADHD medications (Stein et al. [@B32]; Kidwell et al. [@B20]). The impact of ADHD medications on sleep has been debated, with some studies showing deleterious effects on sleep, some studies showing minimal effects on sleep, and other studies showing improvement in sleep parameters after treatment with ADHD medications (Kidwell et al. [@B20]). The potential for different ADHD medications with varying pharmacokinetic profiles to have different impacts on sleep parameters also has been a topic of research and clinical discussion.

Forty to fifty percent of parents report sleep-related problems in their children with ADHD, particularly resistance to bedtime and/or delayed sleep onset (Owens [@B26]). When studies comparing children with ADHD with controls were evaluated, it was noted that children with ADHD had higher scores for bedtime resistance, sleep latency, morning awakening challenges, nighttime awakenings, sleep-disordered breathing, and daytime sleepiness (Cortese et al. [@B11]). Complicating the matter further is that many children with ADHD have comorbid psychiatric conditions, such as anxiety or depression, which also may affect sleep (Mayes et al. [@B23]; Accardo et al. [@B1]).

A population-based ADHD study conducted by the Australian government found that children with ADHD with insomnia had significantly worse psychosocial outcomes, missed more days of school, and their parents also missed more days of work (Sung et al. [@B33]). Primary sleep disorders coexisting with ADHD such as sleep-related movement disorders (Walters et al. [@B34]), circadian sleep disorders (Chiang et al. [@B6]; Gruber et al. [@B16]), and sleep-related breathing disorders (Cortese et al. [@B12]) often further complicate the sleep challenges in children and adolescents with ADHD.

Clinically, children and adolescents with insufficient or poor quality sleep often demonstrate behaviors of inattention and hyperactivity that may be misinterpreted as symptoms of ADHD (Owens [@B26]; Cassoff et al. [@B5]; Hvolby [@B18]; National Sleep Foundation [@B24]). In contrast to adults who generally exhibit fatigue and sleepiness in the face of insufficient or disrupted sleep, children\'s behavioral response to subjective sleepiness may manifest as increased activity levels as well as behavioral and mood dysregulation (Owens [@B26]).

Further complicating these relationships is the potential impact of ADHD stimulant medications on sleep. A recent meta-analysis of articles in which stimulants were used for ADHD found that worsening sleep latency was seen in some patients receiving stimulants and that this finding was more common in patients receiving more frequent stimulant dosing (Kidwell et al. [@B20]). Extended-release stimulant formulations given once daily had less impact on sleep latency than thrice-daily immediate-release dosing. These researchers also found that patients receiving stimulants had poorer sleep efficiency (i.e., time asleep/time in bed) than patients not receiving stimulants. This effect appeared to be attenuated with prolonged dosing (Kidwell et al. [@B20]).

Several clinical trials of long-acting stimulant medication have now examined sleep outcomes as a secondary outcome. Most of these studies have used subjective measures such as parent report. A study of the impact of OROS^®^ methylphenidate (Janssen Pharmaceuticals, Inc., Titusville, NJ) on sleep using the Children\'s Sleep Habits Questionnaire (CSHQ) demonstrated improvement in parasomnias and no overall effect on sleep onset latency, although there was worsening in those children who had sleep complaints (Kim et al. [@B21]). This study also used the objective measure polysomnography and found an increase in stage 2 sleep and improvement in the number of awakenings.

A study of the impact of lisdexamfetamine on sleep in children using the objective measures polysomnography and actigraphy as well as subjective parent report did not find any statistically significant increase in the primary endpoint of latency to persistent sleep on any of the three measures (Giblin and Strobel [@B15]). Subjective sleep measure results indicated the possibility that responses are influenced by sleep hygiene counseling before and throughout the study. These studies demonstrate that assessment of sleep as an outcome in its own right, as opposed to looking at sleep as an adverse event may provide us with a better understanding of the specifics of both the benefit and risk of stimulant treatment to children, facilitate the identification of children at risk, and identify the specific objective and subjective sleep parameters that may be impacted.

Aptensio XR^®^ (Rhodes Pharmaceuticals L.P., Coventry, RI) is a multilayer bead extended-release methylphenidate (MPH-MLR) capsule formulation, in which each bead has 40% of the MPH located in the immediate-release outer layer and 60% of the methylphenidate located in a pH-dependent extended-release layer (Aptensio XR™ prescribing information [@B4]). Administration of MPH-MLR results in a biphasic pattern of methylphenidate plasma concentration with an initial peak at 2 hours postdose, gradually declining concentration over the next 4--6 hours, and a secondary peak ∼8 hours postdose with gradually declining concentration thereafter ([Fig. 1](#f1){ref-type="fig"}) (Adjei et al. [@B2]; Aptensio XR™ prescribing information [@B4]).

![Mean plasma MPH concentration versus time following a single dose of MPH-MLR capsule or sprinkles. MPH, methylphenidate; MPH-MLR, multilayer bead extended-release methylphenidate.](fig-1){#f1}

In an analog classroom study (Study 1), significant improvements in ADHD symptoms were observed 1 hour after administration of MPH-MLR and sustained for ≥12 hours, with no diminution of effect (Wigal et al. [@B36]). The pivotal studies supporting marketing approval for MPH-MLR demonstrated that it is efficacious for ADHD in children and adolescents, as evaluated in both analog classroom and outpatient environments (Wigal et al. [@B36], [@B37]).

Assessment of sleep was included in the design of the MPH-MLR pivotal studies as an exploratory endpoint to investigate the impact of MPH-MLR treatment on parent- and self-reported sleep difficulties. We report the results of analyses of these endpoints to further the understanding of the impact of a long-acting methylphenidate preparation on parent-reported sleep.

Methods {#s002}
=======

Studies {#s003}
-------

Two randomized, double-blind (DB), placebo-controlled, phase 3 studies were included in the MPH-MLR clinical development program (Wigal et al. [@B36], [@B37]). Study 1 ([ClinicalTrials.gov](ClinicalTrials.gov) Identifier: NCT01269463) evaluated the time course of response to MPH-MLR in an analog classroom setting (Wigal and Wigal [@B38]) and included four phases: screening (≤28 days), open label (OL) dose optimization (4 weeks), DB crossover (2 weeks), and follow-up call (Wigal et al. [@B36]). Children (male or female) aged 6--12 years at the time of consent with any of the three subtypes of ADHD as defined by the *Diagnostic and Statistical Manual of Mental Disorders*, fourth edition, text revision (DSM-IV-TR) (American Psychiatric Association 2000) were eligible for inclusion in the study. Exclusion criteria included severe concurrent psychiatric or medical illness and functioning at an estimated intellectual level \<80 on the Wechsler Abbreviated Scale of Intelligence.

During the OL dose-optimization phase, dosing was initiated with MPH-MLR 15 mg and titrated weekly over the next 2--4 weeks to an optimized dose of 15, 20, 30, or 40 mg. Patients were then randomized in a 1:1 ratio to one of two treatment sequence groups (optimized dose--placebo or placebo--optimized dose). The optimized dose or placebo was administered for 1 week, and the patient participated in an analog classroom study day and crossed over to the second treatment and participated in a second analog classroom day. The primary efficacy endpoint was the mean of the DB on-treatment postdose Swanson, Kotkin, Agler, M-Flynn, and Pelham (SKAMP)-total scores over time points 1.0, 2.0, 3.0, 4.5, 6.0, 7.5, 9.0, 10.5, and 12.0 hours during the classroom day.

Study 2 ([ClinicalTrials.gov](ClinicalTrials.gov) Identifier: NCT01239030) was a fixed-dose evaluation of MPH-MLR safety/efficacy with the assigned dose given from day 1 with no titration. The four study phases included screening (≤28 days), DB (1 week), OL dose optimization (11 weeks), and follow-up call (Wigal et al. [@B37]). This study included children and adolescents (male and female) aged 6--18 years at the time of consent with an ADHD diagnosis as defined in the DSM-IV-TR. Exclusion criteria were similar to Study 1.

During the DB phase, patients were randomized (1:1:1:1:1) to receive MPH-MLR 10, 15, 20, or 40 mg, or placebo. During the 11-week OL dose-optimization phase, treatment was initiated with the once-daily MPH-MLR 10 mg dose and titrated (up or down) at weekly intervals until the optimal dose was achieved. MPH-MLR capsules of 10, 15, 20, 30, 40, 50, and 60 mg were available in the OL dose-optimization phase. The primary efficacy endpoint measure was the change from baseline to the end of the DB phase in the clinician-rated ADHD Rating Scale-IV total score.

All participants and/or legal guardians provided written informed consent in both studies before receiving pre-enrollment, psychiatric and medical evaluations. Both studies were conducted in compliance with Good Clinical Practice guidelines of the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use, the United States Code of Federal Regulations that relate to clinical trial conduct, and the principles of the Declaration of Helsinki. Further study details for Studies 1 and 2 have been published elsewhere (Wigal et al. [@B36], [@B37]).

In both studies, sleep was evaluated in children aged 6--12 years using the parent-reported CSHQ as well as the child-reported Sleep Self-Report (SSR). For adolescents aged 13--18 years, modified versions of the Adolescent Sleep Habits Questionnaire (ASHQ; parent report and self-report) were used. In Study 1, sleep assessments were collected at baseline, the end of OL dose-optimization phase (beginning of the DB phase), and weekly during the DB crossover phase. In Study 2, sleep assessments were collected at the beginning and end of the DB phase and again at the end of the OL dose-optimization phase.

Assessments {#s004}
-----------

The CSHQ is a retrospective 48-item parent questionnaire used to examine sleep behavior that has been validated in young children (aged 4--10 years) (Owens et al. [@B28]). It includes items relating to a number of key sleep domains that encompass the major presenting clinical sleep complaints in this age group. Parents are asked to recall sleep behaviors occurring over a typical recent week and to rate the behavior on a three-point scale scored 1--3, with a higher score indicative of more problems.

Ratings for most items were as follows: "usually" if something occurred 5--7 times in a week, "sometimes" if it occurred 2--4 times in a week, or "rarely" if something occurred 0--1 time in a week. Two items required the rating to be "not sleepy," "very sleepy," or "falls asleep." Thirty-three items were grouped into eight subscales: Bedtime Resistance, Sleep Onset Delay, Sleep Duration, Sleep Anxiety, Night Wakings, Parasomnias, Sleep-Disordered Breathing, and Daytime Sleepiness. Scale scores were the sum of the scores for items in the scale. If an item from a scale was not rated, the scale score was taken as missing.

The SSR is a 26-item questionnaire that has been used in previous studies (Owens et al. [@B27], [@B29]) to measure sleep disturbances reported by children themselves. Twenty-three items were grouped into three subscales for this analysis: Bedtime, Sleep Behavior, and Daytime Sleepiness. Scoring of items and scales mirrored the parent-reported version.

The ASHQ was developed to parallel the parent- and self-reported versions of the CSHQ and examines sleep behavior in adolescents (aged 13--18 years); its structure is similar to the CSHQ. The ASHQ-Parent version was administered by clinicians and directed to parents. For each item there were four possible responses (never = 0 × /week; rarely = 1--2 × /week; sometimes = 3--5 × /week; usually = 6--7 × /week). Items were grouped into the following six subscales: Bedtime, Sleep Behavior, Waking During the Night, Morning Waking, Sleep Habits, and Daytime Sleepiness. Item scores ranged from 0 to 3, with higher scores more indicative of sleep problems. In this study, the ASHQ was modified to include a response of "don\'t know." Scoring was taken as the mean of the nonmissing data times the number of items in the scale because of "don\'t know" responses. The clinician administered a slightly different version of the ASHQ to adolescents (ASHQ-Self). ASHQ-Self scoring and groupings were similar to the ASHQ-Parent report.

Analysis {#s005}
--------

In Study 1, the observed DB data were analyzed using an analysis of variance appropriate for a crossover study with terms for subject, treatment, period, and sequence. In Study 2, the change during the DB phase was analyzed using an analysis of covariance appropriate for a parallel study with terms for treatment and site and with each patient\'s baseline score as a covariate with a pairwise comparison of each MPH-MLR treatment to placebo using Dunnett\'s test. In both studies, the analysis of the OL dose-optimization phase in each study was a paired *t*-test comparing the start of study with the end of the OL dose-optimization phase. All *p*-values were two sided.

Results {#s006}
=======

Patient demographics {#s007}
--------------------

Study 1 included 26 patients who completed screening and received at least one dose of study drug and 20 patients who completed SKAMP assessments for all study time points and received the scheduled treatments (Wigal et al. [@B36]). At screening, two patients were receiving psychotropic medication. The mean (standard deviation \[SD\]) optimized dose of MPH-MLR was 25.7 (6.2) mg. Study 2 included 230 patients who completed screening and received at least one dose of study drug, and 221 children and adolescents who completed the ADHD Rating Scale-IV assessments on days 0 and 7 (Wigal et al. [@B37]). At screening, 74 patients were receiving psychotropic medication.

In Study 2, the mean (SD) optimized dose of MPH-MLR was 36.6 (12.8) mg or 0.93 (0.47) mg/kg. The relationship between optimized dose and weight was not statistically significant (linear regression, slope, *p* = 0.1049). In the DB phase, mean MPH-MLR mg/kg doses were as follows: 10 mg (0.27 mg/kg), 15 mg (0.41 mg/kg), 20 mg (0.52 mg/kg), and 40 mg (0.89 mg/kg). In each study, the population was largely white (81% in Study 1, 69% in Study 2) and the majority of patients were male (54% in Study 1, 67% in Study 2) (Wigal et al. [@B36], [@B37]). At study entry, there was evidence of sleep impairment ([Table 1](#T1){ref-type="table"}).

###### 

[Initial Assessments]{.smallcaps}^[a](#tf2){ref-type="table-fn"}^ [of Sleep in the Multilayer Bead Extended-Release Methylphenidate Phase 3 Studies]{.smallcaps}

                               *Study 1 (*n = *26)*   *Study 2*
  ---------------------------- ---------------------- ------------------------
  Mean (SD) CSHQ total score                          
   Parent                      49.1 (10.10)           46.9 (7.84), *n* = 130
  Mean (SD) ASHQ total score                          
   Parent                      NA                     44.8 (13.96), *n* = 74

CSHQ scores \>41 are indicative of a sleep disorder (Owens et al. [@B28]).

Beginning of the study.

ASHQ, Adolescent Sleep Habits Questionnaire; CSHQ, Children\'s Sleep Habits Questionnaire; NA, not applicable (only children aged ≤12 years included in study); SD, standard deviation.

Study 1 {#s008}
-------

During the 4-week OL dose-optimization phase, scores decreased (improved) from baseline for CSHQ total score and Bedtime Resistance, Sleep Duration, Sleep Anxiety, Night Wakings, Parasomnias, and Sleep-Disordered Breathing subscale scores, although the improvement was only significant for Night Wakings ([Table 2](#T2){ref-type="table"}). Scores increased (worsened) for Sleep Onset Delay and Daytime Sleepiness subscale scores, but neither was significant. Individual Sleep Onset Delay subscale scores showed that 66.7% (16/24) of patients had no change, 20.8% (5/24) worsened, and 12.5% (3/24) improved. SSR total score and Bedtime and Daytime Sleepiness subscale scores also improved, while Sleep Behavior subscale score worsened, but none reached statistical significance.

###### 

[Change in Sleep Scores During the 4-Week Open-Label Dose-Optimization Phase (Study 1; *n* = 24)]{.smallcaps}

                                 *Mean (SD) decrease*   p^[a](#tf4){ref-type="table-fn"}^
  ------------------------------ ---------------------- -----------------------------------
  CSHQ-Parent                                           
   Total                         2.1 (7.87)             0.2074
    Bedtime Resistance           1.0 (2.51)             0.0538
    Sleep Onset Delay            −0.1 (0.68)            0.3769
    Sleep Duration               0.2 (2.04)             0.6921
    Sleep Anxiety                0.6 (1.69)             0.0830
    Night Wakings                0.5 (0.93)             0.0243
    Parasomnias                  0.5 (1.38)             0.0674
    Sleep-Disordered Breathing   0.1 (0.45)             0.1853
    Daytime Sleepiness           −0.3 (3.29)            0.7129
  SSR                                                   
   Total                         1.2 (5.70)             0.3100
    Bedtime                      1.0 (3.39)             0.1617
    Sleep Behavior               −0.3 (2.15)            0.5748
    Daytime Sleepiness           0.5 (2.30)             0.3397

*p*-Values are from paired *t*-test for the change from study start to end of the open-label phase.

CSQH, Children\'s Sleep Habits Questionnaire; SD, standard deviation; SSR, Sleep Self-Report.

During the 2-week DB crossover phase, CSHQ ratings for the Sleep Onset Delay subscale were significantly higher (worse) for optimized MPH-MLR dose than placebo (1.9 vs. 1.34, respectively; *p* = 0.0046; [Table 3](#T3){ref-type="table"}), while CSHQ total score and other subscales were not significantly different between placebo and optimized MPH-MLR dose. Individual patient scores for the Sleep Onset Delay subscale showed that MPH-MLR and placebo scores were not different for 60% (12/20) of patients and indicated more problems (higher score) for 40% (8/20) of patients. SSR score for the DB phase did not show any statistically significant difference between placebo and optimized dose for the SSR total or any subscale scores ([Table 2](#T2){ref-type="table"}).

###### 

[Sleep Scores During the 2-Week Double-Blind Crossover Phase (Study 1; Evaluable Population; *n* = 20)]{.smallcaps}

                                 *LS mean*   p^[a](#tf6){ref-type="table-fn"}^   
  ------------------------------ ----------- ----------------------------------- --------
  CSHQ-Parent                                                                    
   Total                         46.5        44.4                                0.1466
    Bedtime Resistance           9.1         8.8                                 0.5342
    Sleep Onset Delay            1.9         1.3                                 0.0046
    Sleep Duration               4.6         4.0                                 0.1282
    Sleep Anxiety                5.4         5.4                                 0.8885
    Night Wakings                3.7         3.5                                 0.3955
    Parasomnias                  8.2         8.1                                 0.4973
    Sleep-Disordered Breathing   3.2         3.2                                 0.6548
    Daytime Sleepiness           13.4        12.9                                0.3052
  SSR                                                                            
   Total                         39.9        41.2                                0.2507
    Bedtime                      21.1        21.5                                0.5642
    Sleep Behavior               11.3        11.8                                0.4142
    Daytime Sleepiness           7.5         7.9                                 0.1992

Mixed-effects analysis of variance, fixed terms for treatment, period, and sequence; random term for subject within sequence.

CSHQ, Children\'s Sleep Habits Questionnaire; LS, least-squares; MPH-MLR, multilayer bead extended-release methylphenidate; SSR, Sleep Self-Report.

Safety data from Study 1 also were reviewed for sleep-related adverse events. Insomnia was reported as an adverse event by 30.8% (8/26) of patients in the OL dose-optimization phase and 0.0% (0/21) and 4.5% (1/22) of patients receiving MPH-MLR or placebo, respectively (DB crossover phase). Discontinuations related to insomnia were few: None during the DB phase and only one of four discontinuations during the OL dose-optimization phase.

Study 2 {#s009}
-------

During the initial 1-week DB fixed-dose phase, there was no significant difference among treatments for CSHQ total or any subscale except for Parasomnias ([Table 4](#T4){ref-type="table"}). For the Parasomnias subscale score, *p*-values from Dunnett\'s multiple comparison follow-up comparison of each MPH-MLR treatment with placebo were significant only for the 10 mg dose (*p* = 0.0170 \[10 mg\], *p* = 0.9071 \[15 mg\], *p* = 0.9674 \[20 mg\], *p* = 0.2338 \[40 mg\]). There was no difference in Sleep Onset Delay subscale score during the DB phase, even with higher MPH-MLR doses. There were no significant treatment differences for changes on the SSR or ASHQ-Parent or ASHQ-Self during the DB phase.

###### 

[Change in Sleep Scores During the 1-Week Double-Blind Phase (Study 2; Evaluable Population; *n* = 221)]{.smallcaps}

                                 *LS mean decrease*   p^[a](#tf8){ref-type="table-fn"}^                        
  ------------------------------ -------------------- ----------------------------------- ------ ------ ------ --------
  CSHQ                                                                                                         
   Total (*n* = 124)             −0.2                 1.2                                 0.9    1.7    1.5    0.5184
    Bedtime Resistance           −0.2                 0.1                                 −0.2   0.3    0.2    0.5214
    Sleep Onset Delay            0.1                  0                                   −0.1   −0.1   0      0.7900
    Sleep Duration               −0.2                 0                                   −0.3   0      0      0.9476
    Sleep Anxiety                −0.2                 0.2                                 0.1    0      0.1    0.4236
    Night Wakings                0.1                  0.1                                 0.1    0      0      0.9859
    Parasomnias                  −0.2                 0.5                                 0.6    0.1    0.7    0.0295
    Sleep-Disordered Breathing   −0.1                 0.1                                 0      0      0.1    0.4216
  Daytime Sleepiness             0.1                  0.6                                 0.6    1.2    0.6    0.5483
  SSR                                                                                                          
   Total (*n* = 135)             −0.7                 1.0                                 2.5    1.1    0.4    0.1604
    Bedtime                      −0.3                 0.5                                 1.1    0.3    0.7    0.4904
    Sleep Behavior               0                    0.2                                 0.1    0.3    0      0.9743
    Daytime Sleepiness           −0.1                 0.4                                 0.7    0.4    0      0.2289
  ASHQ-Parent                                                                                                  
   Total (*n* = 74)              0.9                  4.5                                 3.9    4.9    0.9    0.4485
    Bedtime                      0                    1.8                                 1.1    1.5    −0.7   0.2482
    Sleep Behavior               0.4                  0                                   1.1    1.2    0.6    0.8334
    Waking During the Night      0.4                  0.9                                 0.9    0.7    0.7    0.9528
    Morning Waking               −0.2                 0.2                                 0.1    0      0.1    0.9978
    Sleep Habits                 −0.5                 0.1                                 0.1    0.5    −0.4   0.4594
    Daytime Sleepiness           0.5                  0.3                                 1.3    0.7    0.4    0.9418
  ASHQ-Self                                                                                                    
   Total (*n* = 71)              2.9                  10.4                                4.5    5.8    3.2    0.3219
    Bedtime                      1.0                  0.8                                 0.6    1.1    0.8    0.9966
    Sleep Behavior               0.8                  1.5                                 1.2    1.4    0.8    0.9677
    Waking During the Night      0                    1.5                                 0.4    0.6    0.9    0.4306
    Morning Waking               0.8                  2.0                                 0.3    0.9    1.1    0.7464
    Sleep Habits                 −0.2                 −0.6                                0.6    −0.2   −0.4   0.1845
    Daytime Sleepiness           0.8                  1.6                                 2.1    1.8    0.2    0.1853

Analysis of covariance model has fixed terms for treatment and sites; covariate is baseline score. Sites with \<10 patients combined.

ASHQ, Adolescent Sleep Habits Questionnaire; CSHQ; Children\'s Sleep Habits Questionnaire; LS, least-squares; MPH-MLR, multilayer bead extended-release methylphenidate; SSR, Sleep Self-Report.

During the 11-week OL dose-optimization phase, mean total and all subscale scores decreased from baseline (fewer sleep-related problems) for the CSHQ, SSR, and ASHQ-Parent, and most subscale scores were significant ([Table 5](#T5){ref-type="table"}). At end of OL, CSHQ scores were significantly lower for the following: total score and Bedtime Resistance, Sleep Duration, Night Wakings, Parasomnias, and Daytime Sleepiness subscale scores. ASHQ-Parent total score and Bedtime, Sleep Behavior, and Morning Waking subscale scores were also significantly lower at the end of OL dose optimization. For the ASHQ-Self, all scales decreased significantly, except for the Sleep Habits and Bedtime subscales, which decreased, but not significantly. During the OL dose-optimization phase, CSHQ Sleep Onset Delay subscale score did not change in 59.6% (81/136) of patients, worsened in 16.2% (22/136) of patients, and improved in 24.3% (33/136) of patients.

###### 

[Changes in Sleep Scores During the 11-Week Open-Label Dose-Optimization Phase (Study 2)]{.smallcaps}

                                 n     *Mean (SD) decrease*^[a](#tf10){ref-type="table-fn"}^   p^[b](#tf11){ref-type="table-fn"}^
  ------------------------------ ----- ------------------------------------------------------- ------------------------------------
  CSHQ-Parent                                                                                  
   Total                         122   3.5 (6.44)                                              \<0.001
    Bedtime Resistance           128   0.5 (1.72)                                              0.0013
    Sleep Onset Delay            136   0.1 (0.89)                                              0.1037
    Sleep Duration               132   0.4 (1.64)                                              0.0141
    Sleep Anxiety                129   0.2 (1.34)                                              0.1698
    Night Wakings                129   0.2 (1.16)                                              0.0296
    Parasomnias                  126   0.7 (1.75)                                              \<0.0001
    Sleep-Disordered Breathing   129   0.1 (0.56)                                              0.0858
    Daytime Sleepiness           132   1.5 (3.42)                                              \<0.0001
  SSR                                                                                          
   Total                         129   2.2 (6.18)                                              \<0.0001
    Bedtime                      134   1.0 (4.02)                                              0.0056
    Sleep Behavior               134   0.8 (2.60)                                              0.0008
    Daytime Sleepiness           133   0.6 (1.74)                                              0.0001
  ASHQ-Parent                                                                                  
   Total                         69    6.5 (12.26)                                             \<0.0001
    Bedtime                      69    1.2 (4.40)                                              0.0240
    Sleep Behavior               69    1.4 (3.50)                                              0.0016
    Waking During the Night      69    0.4 (2.46)                                              0.1398
    Morning Waking               69    1.7 (3.59)                                              0.0002
    Sleep Habits                 69    0.3 (1.79)                                              0.1471
    Daytime Sleepiness           69    1.0 (4.67)                                              0.0805
  ASHQ-Self                                                                                    
   Total                         67    5.2 (11.53)                                             0.0004
    Bedtime                      67    0.9 (4.05)                                              0.0731
    Sleep Behavior               67    1.1 (3.23)                                              0.0081
    Waking During the Night      67    0.9 (2.45)                                              0.0033
    Morning Waking               67    1.4 (3.81)                                              0.0031
    Sleep Habits                 67    −0.2 (2.42)                                             0.5668
    Daytime Sleepiness           67    1.0 (4.05)                                              0.0505

Decrease from beginning of the study to end of the OL phase or early termination in the OL phase.

From paired *t*-test.

ASHQ, Adolescent Sleep Habits Questionnaire; CSHQ; Children\'s Sleep Habits Questionnaire; OL, open label; SD, standard deviation; SSR, Sleep Self-Report.

During the 1-week, DB phase, insomnia was reported as an adverse event by 9.8% (18/183) and 2.1% (1/47) of patients receiving MPH-MLR or placebo, respectively. The rate of reported insomnia did not appear to increase as dose increased: 10 mg (5/49 \[10.2%\]), 15 mg (2/44 \[4.5%\]), 20 mg (6/45 \[13.3%\]), and 40 mg (5/45 \[11.1%\]). During the OL dose-optimization phase, 11.8% (26/221) of patients reported insomnia as an adverse event. In the DB phase, 11.1% (1/9) of patients discontinued owing to insomnia. In the OL dose-optimization phase, 19.0% (4/21) of patients discontinued owing to insomnia.

Discussion {#s010}
==========

The results of these studies suggest that while MPH-MLR, an extended-release methylphenidate, negatively impacted some dimensions of sleep such as sleep onset latency, it also had beneficial effects on other dimensions of sleep. Previous research has focused predominantly on psychostimulant-associated "insomnia" as an adverse event loosely defined by the investigator, which is often not further differentiated as difficulty with sleep onset or sleep maintenance. These differences in insomnia definition may account for the apparent discrepancy between no change or improvements in CSHQ sleep parameters and rates of reported insomnia adverse events during the longer study phases (dose-optimization phase in Study 1 and OL phase in Study 2).

The finding in this study that stimulant administration was associated with a delay in sleep onset compared with placebo is similar to a number of other studies of children with ADHD. As noted in the introduction, a meta-analysis of studies that reported sleep data in patients treated with stimulants noted that patients themselves and/or parents of children or adolescents with ADHD more frequently report problems with prolonged sleep onset latency and decreased sleep efficiency (Kidwell et al. [@B20]).

Another meta-analysis of studies that used actigraphy (wristwatch-like device that captures and stores body movement data to approximate sleep/wake patterns) to monitor sleep effects found a significant impact of methylphenidate administration on total sleep time (decreased) (De Crescenzo et al. [@B13]). Both sleep onset latency and total sleep time were negatively impacted by methylphenidate administration in another study of 21 children aged 6--12 years (Corkum et al. [@B9]). In another 8-week randomized crossover study, 37 children aged 10--17 years received extended-release dexmethylphenidate and extended-release mixed amphetamine salts (Santisteban et al. [@B31]). Both medications decreased sleep duration as measured by actigraphy, and there was no significant difference between the two medications. Higher doses were associated with a later sleep onset and shorter sleep duration (Santisteban et al. [@B31]).

In contrast, our findings suggest that while improvement in sleep parameters, as evidenced by a decrease in total and subscale sleep survey scores, was generally not seen over the short duration of the DB phase in each of these studies, there also was no evidence that sleep deteriorated during this time. Furthermore, prolonged administration of MPH-MLR at an optimized dose in the OL phase of both studies appeared to result in some improvement in sleep parameters. As previously described, the possibility that administration of stimulants, including methylphenidate, might have a null or even beneficial effect on some aspects of sleep has been reported in the literature (Kim et al. [@B21]; Giblin and Strobel [@B15]).

Similar to the results of these studies, in a study of once-daily oral or transdermal methylphenidate, there was little evidence suggesting a negative impact of treatment on sleep parameters, particularly once an optimized dose was achieved (Faraone et al. [@B14]). A study of children in Thailand with ADHD aged 5--12 years found no significant differences in sleep difficulties in children who were receiving ADHD treatment with stimulants and those who were not (Chiraphadhanakul et al. [@B7]). An observational sleep study in children with ADHD reported little evidence that supported a substantial effect in objective or subjective measures of sleep (O\'Brien et al. [@B25]); even a third dose of methylphenidate administered late in the day to children with ADHD did not appear to have a negative impact on sleep (Kent et al. [@B19]).

Finally, polysomnography data from children treated with OROS methylphenidate actually showed a significant decrease in the number of awakenings (Kim et al. [@B21]), and subjective measures in another study indicated that nighttime awakenings were improved in children with ADHD treated with thrice-daily methylphenidate (Sangal et al. [@B30]).

In general, subjective reports in these studies were consistent with objective findings, when available. In addition, these subjective measures provided information on parent experience of sleep in their children over time which is different from, but as important as, the objective impact on sleep itself. It is frequently the caregiver report that defines behaviors as a "problem" in the clinical setting and thus determines the level and type of recommended intervention.

The reasons that stimulants might be responsible for some improvements in sleep remain theoretical. It is possible that use of stimulants, at therapeutic levels that are sustained into the evening hours, would reduce ADHD symptoms just before and at bedtime. By mitigating these symptoms, bedtime resistance might be attenuated, facilitating an easier transition to sleep and initiation of sleep itself.

This study has limitations that should be considered in the interpretation of results, some of which relate to measurement issues. Sleep assessment was not the primary objective of either Study 1 or Study 2, and these data are based on patient or parental report; thus, these findings may warrant further investigation with objective measures of sleep such as actigraphy or polysomnography. Studies have generally not demonstrated a correlation between subjective and objective assessments of sleep in children with ADHD (Corkum et al. [@B10]; Wiggs et al. [@B39]; Markovich et al. [@B22]), and it is likely that these various tools measure somewhat different sleep constructs.

Our main goal in this analysis was to assess the impact of MPH-MLR on clinically relevant practical sleep parameters, so we utilized parent- and self-reports as being most legitimately reflective of real-world parent and patient concerns. All the sleep measures were, however, consistently used at all time points in the studies and the results suggest considerable agreement between scales. In addition, the ASHQ-Parent and ASHQ-Self report used in these studies has not been fully validated; furthermore, children aged ≤12 years were included in this group and the CSHQ has only been validated in children aged ≤10 years.

It also should be noted that sleep was assessed by both the parent and the child/adolescent in the studies, and while the improvements in the total score were directionally similar, they were numerically larger when assessed by the parent. There was a discrepancy between some parent- and self-report scores; for example, in Study 1, parents noted a worsening on the Daytime Sleepiness subscale, while children reported an improvement. Similarly, adolescents in Study 2 reported a worsening on the Sleep Habits subscale, while parents reported an improvement. This underscores the importance of querying both children/adolescents and caregivers about sleep.

The DB phase was brief in both studies (active drug was administered for only 1 week). The forced dose randomization to five groups in Study 2, with children systematically over- and undermedicated, is not optimal for looking at drug versus placebo effects on insomnia. Finally, the OL design precludes ruling out unspecific factors such as rater bias and time effects. The argument might be made, for example, that response fatigue (i.e., caregivers being less likely to report problems as time goes on) may have been at least partially responsible for the apparent decrease in sleep symptoms observed during the OL phases. Not all sleep subscale scores declined over time, however, and interestingly, the Sleep-Disordered Breathing subscale, which would not be expected to be impacted by stimulant therapy, did not change significantly during the OL phase in either Study 1 or Study 2.

Children and adolescents with ADHD and sleep difficulties may benefit from receipt of information about healthy sleep practices (Weiss et al. [@B35]) as evidenced by two empirical trials (Hiscock et al. [@B17]; Corkum et al. [@B8]).

Conclusions {#s011}
===========

Overall, the results of these studies replicate previous findings suggesting that extended-release methylphenidate may be associated with short-term subjective reports of sleep onset delay in children and adolescents compared with placebo, but that these effects do not persist or worsen, and there may, in fact, be some improvements in sleep parameters over time, as evidenced by lower total and specific subscale scores during the OL phase on the CSHQ and ASHQ. The findings suggest that adverse sleep effects of stimulants, at least for some children with ADHD, may be transient in nature, and that improvement in ADHD daytime symptoms associated with stimulant administration may have a beneficial impact on sleep. Future studies should address these and other possible mechanisms for the differential effects of stimulants on sleep and sleep behavior in children with ADHD.

Clinical Significance {#s012}
=====================

Overall, the results of this analysis of two studies replicate previous findings that suggest that extended-release methylphenidate may be associated with short-term subjective reports of sleep onset delay compared with placebo; however, the findings also suggest that these effects do not persist or worsen, and there may, in fact, be some improvements in sleep parameters over time. One potential mechanism for improvement in sleep parameters is that reduction in ADHD symptoms in the evening just before and at bedtime could reduce bedtime resistance and facilitate settling and sleep onset.
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